KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Depreciation & Amortization (CF) (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $196000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 80.26% year-over-year to $196000.0; the TTM value through Sep 2025 reached $1.2 million, down 79.55%, while the annual FY2024 figure was $4.4 million, 43.81% down from the prior year.
  • Depreciation & Amortization (CF) reached $196000.0 in Q3 2025 per NKTR's latest filing, down from $214000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $3.7 million in Q1 2022 and bottomed at $196000.0 in Q3 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $2.1 million, with a median of $2.2 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): increased 11.56% in 2021, then plummeted 85.33% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $3.4 million in 2021, then decreased by 7.39% to $3.2 million in 2022, then plummeted by 48.08% to $1.7 million in 2023, then tumbled by 79.9% to $332000.0 in 2024, then crashed by 40.96% to $196000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $196000.0 in Q3 2025, $214000.0 in Q2 2025, and $426000.0 in Q1 2025.